EDP Sciences logo
Web of Conferences logo
Search
Menu
All issues Volume 271 (2021) E3S Web Conf., 271 (2021) 03074 References
Open Access
Issue
E3S Web Conf.
Volume 271, 2021
2021 2nd International Academic Conference on Energy Conservation, Environmental Protection and Energy Science (ICEPE 2021)
Article Number 03074
Number of page(s) 6
Section Research on Energy Chemistry and Chemical Simulation Performance
DOI https://doi.org/10.1051/e3sconf/202127103074
Published online 15 June 2021
  1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A.. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6):394–424(2018) [CrossRef] [PubMed] [Google Scholar]
  2. Nasim F., Sabath B.F., Eapen G.A.. Lung Cancer. Med Clin North Am. 103(3):463–473(2019) [CrossRef] [Google Scholar]
  3. Arbour K.C., Riely G.J.. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. JAMA. 322(8):764–774(2019) [CrossRef] [Google Scholar]
  4. Yao M., Fu P.. Advances in anti-HER2 therapy in metastatic breast cancer. Chin Clin Oncol. 7(3):27(2018) [CrossRef] [Google Scholar]
  5. Loibl S., Gianni L.. HER2-positive breast cancer. Lancet. 389(10087):2415–2429(2017) [CrossRef] [Google Scholar]
  6. Da Silva J., Jouida A., Ancel J., Dalstein V., Routhier J., Delepine G., et al. FHIT (low) /pHER2(high) signature in non-small cell lung cancer is predictive of anti-HER2 molecule efficacy. J Pathol. 251(2):187–199(2020) [CrossRef] [Google Scholar]
  7. Li B.T., Ross D.S., Aisner D.L., Chaft J.E., Hsu M., Kako S.L., et al. HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers. J Thorac Oncol. 11(3):414–419(2016) [CrossRef] [Google Scholar]
  8. Peters S., Stahel R., Bubendorf L., Bonomi P., Villegas A., Kowalski D.M., et al. Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Clin Cancer Res. 25(1):64–72(2019) [CrossRef] [Google Scholar]
  9. Weiner D.B., Nordberg J., Robinson R., Nowell P.C., Gazdar A., Greene M.I., et al. Expression of the neugene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res. 50(2):421–425(1990) [Google Scholar]
  10. Daly J.M., Jannot C.B., Beerli R.R., Graus-Porta D., Maurer F.G., Hynes N.E.. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. Cancer Res. 57(17):3804–3811(1997) [Google Scholar]
  11. Graus-Porta D., Beerli R.R., Hynes N.E.. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol. 15(3):1182–1191(1995) [CrossRef] [Google Scholar]
  12. Riese D.J., Stern D.F. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays. 20(1):41–48(1998) [CrossRef] [Google Scholar]
  13. Spector N.L., Blackwell K.L.. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 27(34):5838–5847(2009) [CrossRef] [Google Scholar]
  14. Arcila M.E., Chaft J.E., Nafa K., Roy-Chowdhuri S., Lau C., Zaidinski M., et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 18(18):4910–4918(2012) [CrossRef] [Google Scholar]
  15. Peters S., Zimmermann S.. Targeted therapy in NSCLC driven by HER2 insertions. Transl Lung Cancer Res. 3(2):84–88(2014) [Google Scholar]
  16. Shigematsu H., Takahashi T., Nomura M., Majmudar K., Suzuki M., Lee H., et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 65(5):1642–1646(2005). [CrossRef] [Google Scholar]
  17. Buttitta F., Barassi F., Fresu G., Felicioni L., Chella A., Paolizzi D., et al. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer. 119(11):2586–2591(2006) [CrossRef] [Google Scholar]
  18. Mazieres J., Peters S., Lepage B., Cortot A.B., Barlesi F., Beau-Faller M., et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 31(16):1997–2003(2013) [CrossRef] [PubMed] [Google Scholar]
  19. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J.. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61(12):4744–4749(2001) [Google Scholar]
  20. Cappuzzo F., Bemis L., Varella-Garcia M.. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med. 354(24):2619–2630(2006) [CrossRef] [Google Scholar]
  21. Mazieres J., Barlesi F., Filleron T., Besse B., Monnet I., Beau-Faller M., et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol. 27(2):281–286(2016) [CrossRef] [PubMed] [Google Scholar]
  22. Langer C.J., Stephenson P., Thor A., Vangel M., Johnson D.H., Eastern Cooperative Oncology Group S. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol. 22(7):1180–1187(2004) [CrossRef] [Google Scholar]
  23. Gatzemeier U., Groth G., Butts C., Van Zandwijk N., Shepherd F., Ardizzoni A., et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol. 15(1):19–27(2004) [CrossRef] [Google Scholar]
  24. Lara P.N., Jr., Laptalo, L., Longmate, J., Lau, D.H., Gandour-Edwards, R., Gumerlock, P.H., et al. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer. 5(4):231–236(2004) [PubMed] [Google Scholar]
  25. Wang Y., Jiang T., Qin Z., Jiang J., Wang Q., Yang S., et al. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Ann Oncol. 30(3):447–455(2019) [PubMed] [Google Scholar]
  26. Li X., Yang C., Wan H., Zhang G., Feng J., Zhang L., et al. Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci. 110:51–61(2017) [PubMed] [Google Scholar]
  27. Ma F., Li Q., Chen S., Zhu W., Fan Y., Wang J., et al. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin Oncol. 35(27):3105–3112(2017) [PubMed] [Google Scholar]
  28. Li B.T., Shen R., Buonocore D., Olah Z.T., Ni A., Ginsberg M.S., et al. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. J Clin Oncol. 36(24):2532–2537(2018) [PubMed] [Google Scholar]
  29. Phillips G.D., Fields C.T., Li G., Dowbenko D., Schaefer G., Miller K., et al. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res. 20(2):456–468(2014) [PubMed] [Google Scholar]
  30. Morimura O., Minami T., Kijima T., Koyama S., Otsuka T., Kinehara Y., et al. Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models. Biochem Biophys Res Commun. 488(4):596–602(2017) [PubMed] [Google Scholar]
  31. Hotta K., Aoe K., Kozuki T., Ohashi K., Ninomiya K., Ichihara E., et al. A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer. J Thorac Oncol. 13(2):273–279(2018) [PubMed] [Google Scholar]
  32. Tsurutani J., Iwata H., Krop I., Janne P.A., Doi T., Takahashi S., et al. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discov. 10(5):688–701(2020) [PubMed] [Google Scholar]
  33. Keam S.J.. Trastuzumab Deruxtecan: First Approval. Drugs. 80(5):501–508(2020) [PubMed] [Google Scholar]
  34. OA04, 05-Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer:Interim Results of DESTINY-Lung01.Presented at :WCLC 2020 Virtual; (January 28-31, 2021) [Google Scholar]
  35. MA11.03-Trastuzumab Deruxtecan in HER2-Mutated Metastatic Non-Small Cell Lung Cancer(NSCLC):Interim Results of DESTINY-Lung01.Presented at : WCLC 2020 Virtual; (January 28-31, 2021) [Google Scholar]
  36. Suzawa K., Toyooka S., Sakaguchi M., Morita M., Yamamoto H., Tomida S., et al. Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations. Cancer Sci. 107(1):45–52(2016) [PubMed] [Google Scholar]
  37. Fang W., Zhao S., Liang Y., Yang Y., Yang L., Dong X., et al. Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma. Oncologist. 25(3):e545–e54(2020) [PubMed] [Google Scholar]
  38. Bose P., Ozer H.. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin Investig Drugs. 18(11):1735–1751(2009) [PubMed] [Google Scholar]
  39. Engelman J.A., Zejnullahu K., Gale C.M., Lifshits E., Gonzales A.J., Shimamura T., et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 67(24):11924–32(2007) [PubMed] [Google Scholar]
  40. Kris M.G., Camidge D.R., Giaccone G., Hida T., Li B.T., O'Connell, J., et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol.26(7):1421–1427(2015). [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.